- Home
- TGLS vs NRIX Comparison
TGLS vs NRIX Comparison
Compare TGLS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGLS | NRIX |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TGLS | NRIX |
|---|---|---|
| Price | $44.64 | $17.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $63.33 | $30.50 |
| AVG Volume (30 Days) | 222.1K | ★ 2.5M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $370,984,000.00 | $76,987,000.00 |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $9.04 | $48.05 |
| P/E Ratio | $63.17 | ★ N/A |
| Revenue Growth | 17.98 | ★ 99.31 |
| 52 Week Low | $37.52 | $8.20 |
| 52 Week High | $83.32 | $22.50 |
Technical Indicators
Market Signals| Indicator | TGLS | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 57.11 |
| Support Level | $44.26 | $16.81 |
| Resistance Level | $46.41 | $17.23 |
| Average True Range (ATR) | 1.60 | 1.31 |
| MACD | 0.27 | 0.12 |
| Stochastic Oscillator | 74.79 | 63.81 |
Price Performance
Historical ComparisonAbout TGLS Tecnoglass Inc.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.